Recent findings and advancements in the detection of designer benzodiazepines: a brief review

1. Greenblatt DJ, Shader RI, Abernethy DR. Current status of benzodiazepines. N Engl J Med 1983;309:410–6. doi: 10.1056/NEJM198308183090705 GreenblattDJ ShaderRI AbernethyDR Current status of benzodiazepines N Engl J Med 1983 309 410 6 10.1056/NEJM198308183090705 Open DOISearch in Google Scholar

2. Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry 2005;66(Suppl 2):9–13. PMID: 15762814 StewartSA The effects of benzodiazepines on cognition J Clin Psychiatry 2005 66 Suppl 2 9 13 15762814 Search in Google Scholar

3. Fisher J, Sanyal C, Frail D, Sketris I. The intended and unintended consequences of benzodiazepine monitoring programmes: a review of the literature. J Clin Pharm Ther 2012;37:7–21. doi: 10.1111/j.1365-2710.2011.01245.x FisherJ SanyalC FrailD SketrisI The intended and unintended consequences of benzodiazepine monitoring programmes: a review of the literature J Clin Pharm Ther 2012 37 7 21 10.1111/j.1365-2710.2011.01245.x Open DOISearch in Google Scholar

4. O'Connor LC, Torrance HJ, McKeown DA. ELISA detection of phenazepam, etizolam, pyrazolam, flubromazepam, diclazepam and delorazepam in blood using Immunalysis^® benzodiazepine kit. J Anal Toxicol 2016;40:159–61. doi: 10.1093/jat/bkv122 O'ConnorLC TorranceHJ McKeownDA ELISA detection of phenazepam, etizolam, pyrazolam, flubromazepam, diclazepam and delorazepam in blood using Immunalysis^® benzodiazepine kit J Anal Toxicol 2016 40 159 61 10.1093/jat/bkv122 Open DOISearch in Google Scholar

5. Villain M, Concheiro M, Cirimele V, Kintz P. Screening method for benzodiazepines and hypnotics in hair at pg/mg level by liquid chromatography-mass spectrometry/mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005;825:72–8. doi: 10.1016/j.jchromb.2004.12.036 VillainM ConcheiroM CirimeleV KintzP Screening method for benzodiazepines and hypnotics in hair at pg/mg level by liquid chromatography-mass spectrometry/mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 2005 825 72 8 10.1016/j.jchromb.2004.12.036 Open DOISearch in Google Scholar

6. Yegles M, Mersch F, Wennig R. Detection of benzodiazepines and other psychotropic drugs in human hair by GC/MS. Forensic Sci Int 1997;84:211–8. doi: 10.1016/s0379-0738(96)02064-6 YeglesM MerschF WennigR Detection of benzodiazepines and other psychotropic drugs in human hair by GC/MS Forensic Sci Int 1997 84 211 8 10.1016/s0379-0738(96)02064-6 Open DOISearch in Google Scholar

7. Nakamura M. Analyses of benzodiazepines and their metabolites in various biological matrices by LC-MS (/MS). Biomed Chromatogr 2011;25:1283–307. doi: 10.1002/bmc.1598 NakamuraM Analyses of benzodiazepines and their metabolites in various biological matrices by LC-MS (/MS) Biomed Chromatogr 2011 25 1283 307 10.1002/bmc.1598 Open DOISearch in Google Scholar

8. Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 2007;32:333–41. doi: 10.1111/j.1365-2710.2007.00829.x FukasawaT SuzukiA OtaniK Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines J Clin Pharm Ther 2007 32 333 41 10.1111/j.1365-2710.2007.00829.x Open DOISearch in Google Scholar

9. Mizuno K, Katoh M, Okumura H, Nakagawa N, Negishi T, Hashizume T, Nakajima M, Yokoi T. Metabolic activation of benzodiazepines by CYP3A4. Drug Metab Dispos 2009;37:345–51. doi: 10.1124/dmd.108.024521 MizunoK KatohM OkumuraH NakagawaN NegishiT HashizumeT NakajimaM YokoiT Metabolic activation of benzodiazepines by CYP3A4 Drug Metab Dispos 2009 37 345 51 10.1124/dmd.108.024521 Open DOISearch in Google Scholar

10. Tani N, Ikeda T, Ishikawa T. Relationship between clock gene expression and CYP2C19 and CYP3A4 with benzodiazepines. Hum Exp Toxicol 2023;42:09603271231171643. doi: 10.1177/09603271231171643 TaniN IkedaT IshikawaT Relationship between clock gene expression and CYP2C19 and CYP3A4 with benzodiazepines Hum Exp Toxicol 2023 42 09603271231171643 10.1177/09603271231171643 Open DOISearch in Google Scholar

11. Achour B, Russell MR, Barber J, Rostami-Hodjegan A. Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5′-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos 2014;42:500–10. doi: 10.1124/dmd.113.055632 AchourB RussellMR BarberJ Rostami-HodjeganA Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5′-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics Drug Metab Dispos 2014 42 500 10 10.1124/dmd.113.055632 Open DOISearch in Google Scholar

12. Pettersson Bergstrand M, Meyer MR, Beck O, Helander A. Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry. Drug Test Anal 2018;10:496–506. doi: 10.1002/dta.2243 Pettersson BergstrandM MeyerMR BeckO HelanderA Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry Drug Test Anal 2018 10 496 506 10.1002/dta.2243 Open DOISearch in Google Scholar

13. Mandrioli R, Mercolini L, Raggi MA. Benzodiazepine metabolism: an analytical perspective. Curr Drug Metab 2008;9:827–44. doi: 10.2174/138920008786049258 MandrioliR MercoliniL RaggiMA Benzodiazepine metabolism: an analytical perspective Curr Drug Metab 2008 9 827 44 10.2174/138920008786049258 Open DOISearch in Google Scholar

14. Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals-implications for problems of long-term use and abuse. Psychopharmacology (Berl) 1997;134:1–37. doi: 10.1007/s002130050422 GriffithsRR WeertsEM Benzodiazepine self-administration in humans and laboratory animals-implications for problems of long-term use and abuse Psychopharmacology (Berl) 1997 134 1 37 10.1007/s002130050422 Open DOISearch in Google Scholar

15. Wu Q, Hu Y, Wang C, Wei W, Gui L, Zeng W, Liu C, Jia W, Miao J, Lan K. Reevaluate in vitro CYP3A index reactions of benzodiazepines and steroids between humans and dogs. Drug Metab Dispos 2022;50:741–9. doi: 10.1124/dmd.122.000864 WuQ HuY WangC WeiW GuiL ZengW LiuC JiaW MiaoJ LanK Reevaluate in vitro CYP3A index reactions of benzodiazepines and steroids between humans and dogs Drug Metab Dispos 2022 50 741 9 10.1124/dmd.122.000864 Open DOISearch in Google Scholar

16. Buening MK, Chang RL, Huang MT, Fortner JG, Wood AW, Conney AH. Activation and inhibition of benzo (a) pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res 1981;41:67–72. PMID: 7448777 BueningMK ChangRL HuangMT FortnerJG WoodAW ConneyAH Activation and inhibition of benzo (a) pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids Cancer Res 1981 41 67 72 7448777 Search in Google Scholar

17. Hallifax D, Rawden HC, Hakooz N, Houston JB. Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines. Drug Metab Dispos 2005;33:1852–8. doi: 10.1124/dmd.105.005389 HallifaxD RawdenHC HakoozN HoustonJB Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines Drug Metab Dispos 2005 33 1852 8 10.1124/dmd.105.005389 Open DOISearch in Google Scholar

18. Nishimoto M, Hashimoto H, Ozaki T, Nagashima S, Nakashima M. Effects of antidepressants on the intraventricular conduction and the incidence of arrhythmias induced by programmed ventricular stimulation in the dog heart after myocardial infarction. Naunyn Schmiedebergs Arch Pharmacol 1990;341:240–45. doi: 10.1007/BF00169737 NishimotoM HashimotoH OzakiT NagashimaS NakashimaM Effects of antidepressants on the intraventricular conduction and the incidence of arrhythmias induced by programmed ventricular stimulation in the dog heart after myocardial infarction Naunyn Schmiedebergs Arch Pharmacol 1990 341 240 45 10.1007/BF00169737 Open DOISearch in Google Scholar

19. Broderick PA. Adinazolam affects biogenic amine release in hippocampal CA1 neuronal circuitry. Brain Res Bull 1991;27:689–92. doi: 10.1016/0361-9230(91)90046-M BroderickPA Adinazolam affects biogenic amine release in hippocampal CA1 neuronal circuitry Brain Res Bull 1991 27 689 92 10.1016/0361-9230(91)90046-M Open DOISearch in Google Scholar

20. Fleishaker JC, Hulst LK, Ekernäs SÅ, Grahnén A. Pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam after oral and intravenous dosing in healthy young and elderly volunteers. J Clin Psychopharmacol 1992;12:403–14. doi: 10.1097/00004714-199212000-00006 FleishakerJC HulstLK EkernäsSÅ GrahnénA Pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam after oral and intravenous dosing in healthy young and elderly volunteers J Clin Psychopharmacol 1992 12 403 14 10.1097/00004714-199212000-00006 Open DOISearch in Google Scholar

21. Bo P, Murelli R, Soragna D, Ferrandi D, Savoldi F. [Electroencephalographic effects of a new triazolobenzodiazepine (Adinazolam) in the rabbit, in Italian]. Boll Soc Ital Biol Sper 1993;69:381–6. PMID: 8148115 BoP MurelliR SoragnaD FerrandiD SavoldiF [Electroencephalographic effects of a new triazolobenzodiazepine (Adinazolam) in the rabbit, in Italian] Boll Soc Ital Biol Sper 1993 69 381 6 8148115 Search in Google Scholar

22. Turmel A, De Montigny C. Sensitization of rat forebrain neurons to serotonin by adinazolam, an antidepressant triazolobenzodiazepine. Eur J Pharmacol 1984;99:241–4. doi: 10.1016/0014-2999(84)90247-4 TurmelA De MontignyC Sensitization of rat forebrain neurons to serotonin by adinazolam, an antidepressant triazolobenzodiazepine Eur J Pharmacol 1984 99 241 4 10.1016/0014-2999(84)90247-4 Open DOISearch in Google Scholar

23. Fleishaker JC, Phillips JP. Adinazolam pharmacokinetics and behavioral effects following administration of 20–60 mg oral doses of its mesylate salt in healthy volunteers. Psychopharmacology 1989;99:34–9. doi: 10.1007/BF00634449 FleishakerJC PhillipsJP Adinazolam pharmacokinetics and behavioral effects following administration of 20–60 mg oral doses of its mesylate salt in healthy volunteers Psychopharmacology 1989 99 34 9 10.1007/BF00634449 Open DOISearch in Google Scholar

24. Brunetti P, Giorgetti R, Tagliabracci A, Huestis MA, Busardò FP. Designer benzodiazepines: a review of toxicology and public health risks. Pharmaceuticals (Basel) 2021;14(6):560. doi: 10.3390/ph14060560 BrunettiP GiorgettiR TagliabracciA HuestisMA BusardòFP Designer benzodiazepines: a review of toxicology and public health risks Pharmaceuticals (Basel) 2021 14 6 560 10.3390/ph14060560 Open DOISearch in Google Scholar

25. Linnoila M, Stapleton JM, Lister R, Moss H, Lane E, Granger A, Greenblatt DJ, Eckardt MJ. Effects of adinazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. Eur J Clin Pharmacol 1990;38:371–7. doi: 10.1007/BF00315578 LinnoilaM StapletonJM ListerR MossH LaneE GrangerA GreenblattDJ EckardtMJ Effects of adinazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers Eur J Clin Pharmacol 1990 38 371 7 10.1007/BF00315578 Open DOISearch in Google Scholar

26. Venkatakrishnan K, Culm KE, Ehrenberg BL, Harmatz JS, Corbett KE, Fleishaker JC, Greenblatt DJ. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. J Clin Pharmacol 2005;45:529–37. doi: 10.1177/0091270004269105 VenkatakrishnanK CulmKE EhrenbergBL HarmatzJS CorbettKE FleishakerJC GreenblattDJ Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers J Clin Pharmacol 2005 45 529 37 10.1177/0091270004269105 Open DOISearch in Google Scholar

27. Maskell PD, Parks C, Button J, Liu H, McKeown DA. Clarification of the correct nomenclature of the amino metabolite of clonazolam: 8-aminoclonazolam. J Anal Toxicol 2021;45(2):e1–2. doi: 10.1093/jat/bkaa169 MaskellPD ParksC ButtonJ LiuH McKeownDA Clarification of the correct nomenclature of the amino metabolite of clonazolam: 8-aminoclonazolam J Anal Toxicol 2021 45 2 e1 2 10.1093/jat/bkaa169 Open DOISearch in Google Scholar

28. Sommerfeld-Klatta K, Łukasik-Głębocka M, Teżyk A, Panieński P, Żaba C, Zielińska-Psuja B. Clonazolam a new designer benzodiazepine intoxication confirmed by blood concentration. Forensic Sci Int 2020;310:110237. doi: 10.1016/j.forsciint.2020.110237 Sommerfeld-KlattaK Łukasik-GłębockaM TeżykA PanieńskiP ŻabaC Zielińska-PsujaB Clonazolam a new designer benzodiazepine intoxication confirmed by blood concentration Forensic Sci Int 2020 310 110237 10.1016/j.forsciint.2020.110237 Open DOISearch in Google Scholar

29. European Monitoring Centre for Drugs and Drug Addiction. EMCDDA-Europol 2014 Annual Report on the Implementation of Council Decision 2005/387/JHA [displayed12 November 2023]. Available at https://www.emcdda.europa.eu/system/files/publications/1018/TDAN15001ENN.pdf European Monitoring Centre for Drugs and Drug Addiction EMCDDA-Europol 2014 Annual Report on the Implementation of Council Decision 2005/387/JHA [displayed12 November 2023] Available at https://www.emcdda.europa.eu/system/files/publications/1018/TDAN15001ENN.pdf Search in Google Scholar

30. El Balkhi S, Chaslot M, Picard N, Dulaurent S, Delage M, Mathieu O, Saint-Marcoux F. Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer. Int J Legal Med 2017;131:979–88. doi: 10.1007/s00414-017-1541-6 El BalkhiS ChaslotM PicardN DulaurentS DelageM MathieuO Saint-MarcouxF Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer Int J Legal Med 2017 131 979 88 10.1007/s00414-017-1541-6 Open DOISearch in Google Scholar

31. Sommerfeld-Klatta K, Łukasik-Głębocka M, Teżyk A, Panieński P, Żaba C, Zielińska-Psuja B. Clonazolam a new designer benzodiazepine intoxication confirmed by blood concentration. Forensic Sci Int 2020;310:110237. doi: 10.1016/j.forsciint.2020.110237 Sommerfeld-KlattaK Łukasik-GłębockaM TeżykA PanieńskiP ŻabaC Zielińska-PsujaB Clonazolam a new designer benzodiazepine intoxication confirmed by blood concentration Forensic Sci Int 2020 310 110237 10.1016/j.forsciint.2020.110237 Open DOISearch in Google Scholar

32. Runnstrom M, Kalra SS, Lascano J, Patel DC. Overdose from designer benzodiazepine Diclazepam. QJM Int J Med 2020;113:122–4. doi: 10.1093/qjmed/hcz247 RunnstromM KalraSS LascanoJ PatelDC Overdose from designer benzodiazepine Diclazepam QJM Int J Med 2020 113 122 4 10.1093/qjmed/hcz247 Open DOISearch in Google Scholar

33. Moosmann B, Bisel P, Auwärter V. Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. Drug Test Anal 2014;6:757–63. doi: 10.1002/dta.1628 MoosmannB BiselP AuwärterV Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics Drug Test Anal 2014 6 757 63 10.1002/dta.1628 Open DOISearch in Google Scholar

34. Nielsen S, McAuley A. Etizolam: A rapid review on pharmacology, non-medical use and harms. Drug Alcohol Rev 2020;39:330–6. doi: 10.1111/dar.13052 NielsenS McAuleyA Etizolam: A rapid review on pharmacology, non-medical use and harms Drug Alcohol Rev 2020 39 330 6 10.1111/dar.13052 Open DOISearch in Google Scholar

35. Al Bahri AA, Hamnett HJ. Etizolam and its major metabolites: a short review. J Anal Toxicol 2023;47:216–26. doi: 10.1093/jat/bkac096 Al BahriAA HamnettHJ Etizolam and its major metabolites: a short review J Anal Toxicol 2023 47 216 26 10.1093/jat/bkac096 Open DOISearch in Google Scholar

36. O'Connell CW, Sadler CA, Tolia VM, Ly BT, Saitman AM, Fitzgerald RL. Overdose of etizolam: the abuse and rise of a benzodiazepine analog. Ann Emerg Med 2015;65:465–6. doi: 10.1016/j.annemergmed.2014.12.019 O'ConnellCW SadlerCA ToliaVM LyBT SaitmanAM FitzgeraldRL Overdose of etizolam: the abuse and rise of a benzodiazepine analog Ann Emerg Med 2015 65 465 6 10.1016/j.annemergmed.2014.12.019 Open DOISearch in Google Scholar

37. Wagmann L, Manier SK, Bambauer TP, Felske C, Eckstein N, Flockerzi V, Meyer MR. Toxicokinetics and analytical toxicology of flualprazolam: metabolic fate, isozyme mapping, human plasma concentration and main urinary excretion products. J Anal Toxicol 2020;44:549–58. doi: 10.1093/jat/bkaa019 WagmannL ManierSK BambauerTP FelskeC EcksteinN FlockerziV MeyerMR Toxicokinetics and analytical toxicology of flualprazolam: metabolic fate, isozyme mapping, human plasma concentration and main urinary excretion products J Anal Toxicol 2020 44 549 58 10.1093/jat/bkaa019 Open DOISearch in Google Scholar

38. Mercurio N, Triebold C, Coleman D. Driving under the influence of flualprazolam: 10 case reports. J Anal Toxicol 2022;46(2):e78–81. doi: 10.1093/jat/bkab105 MercurioN TrieboldC ColemanD Driving under the influence of flualprazolam: 10 case reports J Anal Toxicol 2022 46 2 e78 81 10.1093/jat/bkab105 Open DOISearch in Google Scholar

39. Kriikku P, Rasanen I, Ojanperä I, Thelander G, Kronstrand R, Vikingsson S. Femoral blood concentrations of flualprazolam in 33 postmortem cases. Forensic Sci Int 2020;307:110101. doi: 10.1016/j.forsciint.2019.110101 KriikkuP RasanenI OjanperäI ThelanderG KronstrandR VikingssonS Femoral blood concentrations of flualprazolam in 33 postmortem cases Forensic Sci Int 2020 307 110101 10.1016/j.forsciint.2019.110101 Open DOISearch in Google Scholar

40. Moosmann B, Huppertz LM, Hutter M, Buchwald A, Ferlaino S, Auwärter V. Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics. J Mass Spectrom 2013;48:1150–9. doi: 10.1002/jms.3279 MoosmannB HuppertzLM HutterM BuchwaldA FerlainoS AuwärterV Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics J Mass Spectrom 2013 48 1150 9 10.1002/jms.3279 Open DOISearch in Google Scholar

41. Heide G, Høiseth G, Middelkoop G, Øiestad ÅML. Blood concentrations of designer benzodiazepines: relation to impairment and findings in forensic cases. J Anal Toxicol 2020;44:905–14. doi: 10.1093/jat/bkaa043 HeideG HøisethG MiddelkoopG ØiestadÅML Blood concentrations of designer benzodiazepines: relation to impairment and findings in forensic cases J Anal Toxicol 2020 44 905 14 10.1093/jat/bkaa043 Open DOISearch in Google Scholar

42. Huppertz LM, Moosmann B, Auwärter V. Flubromazolam - basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. Drug Test Anal 2018;10:206–11. doi: 10.1002/dta.2203 HuppertzLM MoosmannB AuwärterV Flubromazolam - basic pharmacokinetic evaluation of a highly potent designer benzodiazepine Drug Test Anal 2018 10 206 11 10.1002/dta.2203 Open DOISearch in Google Scholar

43. Łukasik-Głębocka M, Sommerfeld K, Teżyk A, Zielińska-Psuja B, Panieński P, Żaba C. Flubromazolam – A new life-threatening designer benzodiazepine. Clin Toxicol 2016;54:66–8. doi: 10.3109/15563650.2015.1112907 Łukasik-GłębockaM SommerfeldK TeżykA Zielińska-PsujaB PanieńskiP ŻabaC Flubromazolam – A new life-threatening designer benzodiazepine Clin Toxicol 2016 54 66 8 10.3109/15563650.2015.1112907 Open DOISearch in Google Scholar

44. Abdul K, Hikin L, Smith P, Kurimbokus H, Ashong E, Couchman L, Morley SR. Flubromazolam: detection in five post-mortem cases. Med Sci Law 2020;60:266–9. doi: 10.1177/0025802420950273 AbdulK HikinL SmithP KurimbokusH AshongE CouchmanL MorleySR Flubromazolam: detection in five post-mortem cases Med Sci Law 2020 60 266 9 10.1177/0025802420950273 Open DOISearch in Google Scholar

45. Maskell PD, De Paoli G, Nitin Seetohul L, Pounder DJ. Phenazepam: the drug that came in from the cold. J Forensic Leg Med 2012;19:122–5. doi: 10.1016/j.jflm.2011.12.014 MaskellPD De PaoliG Nitin SeetohulL PounderDJ Phenazepam: the drug that came in from the cold J Forensic Leg Med 2012 19 122 5 10.1016/j.jflm.2011.12.014 Open DOISearch in Google Scholar

46. Stephenson JB, Golz DE, Brasher MJ. Phenazepam and its effects on driving. J Anal Toxicol 2013;37:25–9. doi: 10.1093/jat/bks080 StephensonJB GolzDE BrasherMJ Phenazepam and its effects on driving J Anal Toxicol 2013 37 25 9 10.1093/jat/bks080 Open DOISearch in Google Scholar

47. Kriikku P, Wilhelm L, Rintatalo J, Hurme J, Kramer J, Ojanperä I. Phenazepam abuse in Finland: findings from apprehended drivers, post-mortem cases and police confiscations. Forensic Sci Int 2012;220:111–7. doi: 10.1016/j.forsciint.2012.02.006 KriikkuP WilhelmL RintataloJ HurmeJ KramerJ OjanperäI Phenazepam abuse in Finland: findings from apprehended drivers, post-mortem cases and police confiscations Forensic Sci Int 2012 220 111 7 10.1016/j.forsciint.2012.02.006 Open DOISearch in Google Scholar

48. Corkery JM, Schifano F, Ghodse AH. Phenazepam abuse in the UK: an emerging problem causing serious adverse health problems, including death. Hum Psychopharmacol Clin Exp 2012;27:254–61. doi: 10.1002/hup.2222 CorkeryJM SchifanoF GhodseAH Phenazepam abuse in the UK: an emerging problem causing serious adverse health problems, including death Hum Psychopharmacol Clin Exp 2012 27 254 61 10.1002/hup.2222 Open DOISearch in Google Scholar

49. Hester JB Jr, Von Voigtlander P. 6-Aryl-4H-s-triazolo [4, 3-a][1, 4] benzodiazepines. Influence of 1-substitution on pharmacological activity. J Med Chem 1979;22:1390–8. doi: 10.1021/jm00197a021 HesterJBJr Von VoigtlanderP 6-Aryl-4H-s-triazolo [4, 3-a][1, 4] benzodiazepine. Influence of 1-substitution on pharmacological activity J Med Chem 1979 22 1390 8 10.1021/jm00197a021 Open DOISearch in Google Scholar

50. European Monitoring Centre for Drugs and Drug Addiction. Annual report 2021 on the state of the drugs problem in Europe [displayed 24 November 2023]. Available at https://www.emcdda.europa.eu/system/files/media/publications/documents/973/TDAC12001ENC_.pdf European Monitoring Centre for Drugs and Drug Addiction Annual report 2021 on the state of the drugs problem in Europe [displayed 24 November 2023] Available at https://www.emcdda.europa.eu/system/files/media/publications/documents/973/TDAC12001ENC_.pdf Search in Google Scholar

51. Moosmann B, Hutter M, Huppertz LM, Ferlaino S, Redlingshöfer L, Auwärter V. Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. Forensic Toxicol 2013;31:263–71. doi: 10.1007/s11419-013-0187-4 MoosmannB HutterM HuppertzLM FerlainoS RedlingshöferL AuwärterV Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine Forensic Toxicol 2013 31 263 71 10.1007/s11419-013-0187-4 Open DOISearch in Google Scholar

52. Lehmann S, Sczyslo A, Froch-Cortis J, Rothschild MA, Thevis M, Andresen-Streichert H, Mercer-Chalmers-Bender K. Organ distribution of diclazepam, pyrazolam and 3-fluorophenmetrazine. Forensic Sci Int 2019;303:109959. doi: 10.1016/j.forsciint.2019.109959 LehmannS SczysloA Froch-CortisJ RothschildMA ThevisM Andresen-StreichertH Mercer-Chalmers-BenderK Organ distribution of diclazepam, pyrazolam and 3-fluorophenmetrazine Forensic Sci Int 2019 303 109959 10.1016/j.forsciint.2019.109959 Open DOISearch in Google Scholar

53. Pettersson Bergstrand M, Helander A, Beck O. Development and application of a multi-component LC–MS/MS method for determination of designer benzodiazepines in urine. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1035:104–10. doi: 10.1016/j.jchromb.2016.08.047 Pettersson BergstrandM HelanderA BeckO Development and application of a multi-component LC–MS/MS method for determination of designer benzodiazepines in urine J Chromatogr B Analyt Technol Biomed Life Sci 2016 1035 104 10 10.1016/j.jchromb.2016.08.047 Open DOISearch in Google Scholar

54. Mastrovito RA, Papsun DM, Logan BK. The development and validation of a novel designer benzodiazepines panel by LC–MS-MS. J Anal Toxicol 2021;45:423–8. doi: 10.1093/jat/bkab013 MastrovitoRA PapsunDM LoganBK The development and validation of a novel designer benzodiazepines panel by LC–MS-MS J Anal Toxicol 2021 45 423 8 10.1093/jat/bkab013 Open DOISearch in Google Scholar

55. Behnoush B, Sheikhazadi A, Bazmi E, Fattahi A, Sheikhazadi E, Saberi Anary SH. Comparison of UHPLC and HPLC in benzodiazepines analysis of postmortem samples: a case-control study. Medicine (Baltimore) 2015;94(14):e640. doi: 10.1097/MD.0000000000000640 BehnoushB SheikhazadiA BazmiE FattahiA SheikhazadiE Saberi AnarySH Comparison of UHPLC and HPLC in benzodiazepines analysis of postmortem samples: a case-control study Medicine (Baltimore) 2015 94 14 e640 10.1097/MD.0000000000000640 Open DOISearch in Google Scholar

56. Vårdal L, Wong G, Øiestad ÅML, Pedersen-Bjergaard S, Gjelstad A, Øiestad EL. Rapid determination of designer benzodiazepines, benzodiazepines, and Z-hypnotics in whole blood using parallel artificial liquid membrane extraction and UHPLC-MS/MS. Anal Bioanal Chem 2018;410:4967–78. doi: 10.1007/s00216-018-1147-y VårdalL WongG ØiestadÅML Pedersen-BjergaardS GjelstadA ØiestadEL Rapid determination of designer benzodiazepines, benzodiazepines, and Z-hypnotics in whole blood using parallel artificial liquid membrane extraction and UHPLC-MS/MS Anal Bioanal Chem 2018 410 4967 78 10.1007/s00216-018-1147-y Open DOISearch in Google Scholar

57. Schaefer N, Peters B, Schmidt P, Ewald AH. Development and validation of two LC-MS/MS methods for the detection and quantification of amphetamines, designer amphetamines, benzoylecgonine, benzodiazepines, opiates, and opioids in urine using turbulent flow chromatography. Anal Bioanal Chem 2013;405:247–58. doi: 10.1007/s00216-012-6458-9 SchaeferN PetersB SchmidtP EwaldAH Development and validation of two LC-MS/MS methods for the detection and quantification of amphetamines, designer amphetamines, benzoylecgonine, benzodiazepines, opiates, and opioids in urine using turbulent flow chromatography Anal Bioanal Chem 2013 405 247 58 10.1007/s00216-012-6458-9 Open DOISearch in Google Scholar

58. Racamonde I, Rodil R, Quintana JB, Villaverde-de-Sáa E, Cela R. Determination of benzodiazepines, related pharmaceuticals and metabolites in water by solid-phase extraction and liquid-chromatography-tandem mass spectrometry. J Chromatogr A 2014;1352:69–79. doi: 10.1016/j.chroma.2014.05.064 RacamondeI RodilR QuintanaJB Villaverde-de-SáaE CelaR Determination of benzodiazepines, related pharmaceuticals and metabolites in water by solid-phase extraction and liquid-chromatography-tandem mass spectrometry J Chromatogr A 2014 1352 69 79 10.1016/j.chroma.2014.05.064 Open DOISearch in Google Scholar

59. Nissilä T, Backman N, Kolmonen M, Leinonen A, Kiriazis A, Yli-Kauhaluoma J, Sainiemi L, Kostiainen R, Franssila S, Ketola RA. Rotating multitip micropillar array electrospray ionization-mass spectrometry for rapid analysis and high-throughput screening. Int J Mass Spectrom 2012;310:65–71. doi: 10.1016/j.ijms.2011.11.013 NissiläT BackmanN KolmonenM LeinonenA KiriazisA Yli-KauhaluomaJ SainiemiL KostiainenR FranssilaS KetolaRA Rotating multitip micropillar array electrospray ionization-mass spectrometry for rapid analysis and high-throughput screening Int J Mass Spectrom 2012 310 65 71 10.1016/j.ijms.2011.11.013 Open DOISearch in Google Scholar

60. O'Donnell RM, Sun X, Harrington P de B. Pharmaceutical applications of ion mobility spectrometry. TrAC Trends Anal Chem 2008;27:44–53. doi: 10.1016/j.trac.2007.10.014 O'DonnellRM SunX HarringtonP de B Pharmaceutical applications of ion mobility spectrometry TrAC Trends Anal Chem 2008 27 44 53 10.1016/j.trac.2007.10.014 Open DOISearch in Google Scholar

61. Atkinson K, Beretta E, Brown J, Castrodad M, Chen Y, Cosgrove J, Du P, Litchfield J, Makowski M, Martin K, McLellan TJ, Neagu C, Perry DA, Piotrowski DW, Steppan CM, Trilles R. N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors. Bioorg Med Chem Lett 2011;21:1621–5. doi: 10.1016/j.bmcl.2011.01.113 AtkinsonK BerettaE BrownJ CastrodadM ChenY CosgroveJ DuP LitchfieldJ MakowskiM MartinK McLellanTJ NeaguC PerryDA PiotrowskiDW SteppanCM TrillesR N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors Bioorg Med Chem Lett 2011 21 1621 5 10.1016/j.bmcl.2011.01.113 Open DOISearch in Google Scholar

62. McIntire GL, Morris AA, Hitchcock JC, Enders J. Rapid analysis of selected benzodiazepines by automated SPE–MS-MS. LCGC Suppl 2015;13(2):8–15. McIntireGL MorrisAA HitchcockJC EndersJ Rapid analysis of selected benzodiazepines by automated SPE–MS-MS LCGC Suppl 2015 13 2 8 15 Search in Google Scholar

63. Beduk D, Beduk T, de Oliveira Filho JI, Ait Lahcen A, Aldemir E, Guler Celik E, Timur S. Smart multiplex point-of-care platform for simultaneous drug monitoring. ACS Appl Mater Interfaces 2023;15:37247–58. doi: 10.1021/acsami.3c06461 BedukD BedukT de Oliveira FilhoJI Ait LahcenA AldemirE Guler CelikE TimurS Smart multiplex point-of-care platform for simultaneous drug monitoring ACS Appl Mater Interfaces 2023 15 37247 58 10.1021/acsami.3c06461 Open DOISearch in Google Scholar

64. de Jong LAA, Jeronimus-Stratingh CM, Cremers TIFH. Development of a multiplex non-radioactive receptor assay: the benzodiazepine receptor, the serotonin transporter and the β-adrenergic receptor. Rapid Commun Mass Spectrom 2007;21:567–72. doi: 10.1002/rcm.2869 de JongLAA Jeronimus-StratinghCM CremersTIFH Development of a multiplex non-radioactive receptor assay: the benzodiazepine receptor, the serotonin transporter and the β-adrenergic receptor Rapid Commun Mass Spectrom 2007 21 567 72 10.1002/rcm.2869 Open DOISearch in Google Scholar

65. Fitzgerald RL, Rexin DA, Herold DA. Detecting benzodiazepines: immunoassays compared with negative chemical ionization gas chromatography/mass spectrometry. Clin Chem 1994;40:373–80. doi: 10.1093/clinchem/40.3.373 FitzgeraldRL RexinDA HeroldDA Detecting benzodiazepines: immunoassays compared with negative chemical ionization gas chromatography/mass spectrometry Clin Chem 1994 40 373 80 10.1093/clinchem/40.3.373 Open DOISearch in Google Scholar

66. Wang J, Wang Y, Pan Y, Feng L, Chen D, Liu Z, Peng D, Yuan Z. Preparation of a broadly specific monoclonal antibody-based indirect competitive ELISA for the detection of benzodiazepines in edible animal tissues and feed. Food Anal Methods 2016;9:3407–19. doi: 10.1007/s12161-016-0528-0 WangJ WangY PanY FengL ChenD LiuZ PengD YuanZ Preparation of a broadly specific monoclonal antibody-based indirect competitive ELISA for the detection of benzodiazepines in edible animal tissues and feed Food Anal Methods 2016 9 3407 19 10.1007/s12161-016-0528-0 Open DOISearch in Google Scholar

67. Darragh A, Snyder ML, Ptolemy AS, Melanson S. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain. Pain Physician 2014;17:359–66. PMID: 25054395 DarraghA SnyderML PtolemyAS MelansonS KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain Pain Physician 2014 17 359 66 25054395 Search in Google Scholar

68. Bertol E, Vaiano F, Furlanetto S, Mari F. Cross-reactivities and structure-reactivity relationships of six benzodiazepines to EMIT^® immunoassay. J Pharm Biomed Anal 2013;84:168–72. doi: 10.1016/j.jpba.2013.05.026 BertolE VaianoF FurlanettoS MariF Cross-reactivities and structure-reactivity relationships of six benzodiazepines to EMIT^® immunoassay J Pharm Biomed Anal 2013 84 168 72 10.1016/j.jpba.2013.05.026 Open DOISearch in Google Scholar

69. Moretti M, Freni F, Tomaciello I, Vignali C, Groppi A, Visonà SD, Tajana L, Osculati AMM, Morini L. Determination of benzodiazepines in blood and in dried blood spots collected from post-mortem samples and evaluation of the stability over a three-month period. Drug Test Anal 2019;11:1403–11. doi: 10.1002/dta.2653 MorettiM FreniF TomacielloI VignaliC GroppiA VisonàSD TajanaL OsculatiAMM MoriniL Determination of benzodiazepines in blood and in dried blood spots collected from post-mortem samples and evaluation of the stability over a three-month period Drug Test Anal 2019 11 1403 11 10.1002/dta.2653 Open DOISearch in Google Scholar

70. Mestad IO, Gjelstad A, Pedersen-Bjergaard S, Øiestad EL. Green and sustainable drug analysis - Combining microsampling and microextraction of drugs of abuse. Sustain Chem Pharm 2021;24(7):100517. doi: 10.1016/j.scp.2021.100517 MestadIO GjelstadA Pedersen-BjergaardS ØiestadEL Green and sustainable drug analysis - Combining microsampling and microextraction of drugs of abuse Sustain Chem Pharm 2021 24 7 100517 10.1016/j.scp.2021.100517 Open DOISearch in Google Scholar

71. Gundersen POM, Broecker S, Slørdal L, Spigset O, Josefsson M. Retrospective screening of synthetic cannabinoids, synthetic opioids and designer benzodiazepines in data files from forensic post mortem samples analysed by UHPLC-QTOF-MS from 2014 to 2018. Forensic Sci Int 2020;311:110274. doi: 10.1016/j.forsciint.2020.110274 GundersenPOM BroeckerS SlørdalL SpigsetO JosefssonM Retrospective screening of synthetic cannabinoids, synthetic opioids and designer benzodiazepines in data files from forensic post mortem samples analysed by UHPLC-QTOF-MS from 2014 to 2018 Forensic Sci Int 2020 311 110274 10.1016/j.forsciint.2020.110274 Open DOISearch in Google Scholar

72. Yao W, Fan Z, Zhang S. Poly(N-vinylcarbazole-co-divinylbenzene) monolith microextraction coupled to liquid chromatography-high resolution Orbitrap mass spectrometry to analyse benzodiazepines in beer and urine. J Chromatogr A 2016;1465:55–62. doi: 10.1016/j.chroma.2016.08.064 YaoW FanZ ZhangS Poly(N-vinylcarbazole-co-divinylbenzene) monolith microextraction coupled to liquid chromatography-high resolution Orbitrap mass spectrometry to analyse benzodiazepines in beer and urine J Chromatogr A 2016 1465 55 62 10.1016/j.chroma.2016.08.064 Open DOISearch in Google Scholar